Welcome to our dedicated page for Microbot Medical SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Microbot Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Microbot Medical's regulatory disclosures and financial reporting.
Microbot Medical Inc. filed its Form 10-Q for the quarter ended June 30, 2026 and reported that second-quarter revenue and customer counts grew by more than 100% versus the first quarter of 2026, driven by repeat orders, expanded utilization and new customer acquisitions following the Full Market Release of its LIBERTY Endovascular Robotic System in mid-April.
The company expanded adoption of LIBERTY across additional hospital sites and U.S. states, broadened its sales footprint from four to eight sales territories, and entered an agreement with Lovell Government Services Inc. to access more than 2,000 government healthcare facilities. It also partnered with Sanmina to establish a second manufacturing site and achieved a key regulatory milestone as Israel granted marketing clearance, the first jurisdiction outside the U.S. to do so. Management highlighted ongoing cost reduction initiatives aimed at substantially lowering cost of revenue.
Microbot Medical Inc. reported initial commercial revenue from the LIBERTY® Endovascular Robotic System while remaining in a development-stage loss position. For the quarter ended June 30, 2026, revenue was $241,000, all from LIBERTY system sales, and $346,000 for the first half of 2026. Cost of revenues of $884,000 in the quarter and $987,000 year-to-date resulted in negative gross margin as early production and customer concessions weighed on costs.
Research and development expenses were $1.9 million in the quarter and $3.2 million for six months, while sales, general and administrative expenses rose to $3.7 million for the quarter and $6.7 million year-to-date as the company built out commercialization capabilities. Net loss widened to $5.6 million for the quarter and $9.3 million for six months, reflecting higher operating spending and the absence of prior-year one-time other income. Operating cash outflow was $10.0 million in the first half.
Liquidity remains strong, with $67.4 million in cash equivalents and marketable securities as of June 30, 2026 and shareholders’ equity of $68.9 million. Management concludes these resources are sufficient to fund operations for more than 12 months, but the company expects continued losses as it scales LIBERTY manufacturing and sales. Operations and key suppliers are concentrated in Israel, and the company highlights regional conflict as an ongoing risk it is monitoring.
Microbot Medical Inc. updated the compensation terms for its Chief Financial Officer, Rachel Vaknin, by entering into Addendum #4 to her Employment Agreement. The addendum increases her annual base salary to NIS 864,000, described as the equivalent of $288,000 using a presumed 3:1 NIS-to-U.S. dollar exchange rate. The higher salary is effective as of August 1, 2026. The company characterizes this as a material definitive agreement related to executive employment, and the full terms are set out in the addendum referenced as an exhibit.
Microbot Medical Inc. reports that CEO, President and Chairman Harel Gadot will participate in the Society of Robotic Surgery annual meeting in Fort Lauderdale, Florida, held July 23-26, 2026. He will speak on a “Neurovascular Robotics” panel and present an overview of the endovascular robotic market via livestream.
The company notes recent FDA clearance for its single-use LIBERTY® Endovascular Robotic System, describes growing adoption at leading U.S. academic centers for peripheral endovascular procedures, and highlights winning Surgical Robotics Technology’s Innovative Start-Up Award, which recognizes technologically advanced solutions with potential for broad healthcare impact.
Microbot Medical Inc. reports strong commercial momentum for its LIBERTY Endovascular Robotic System in the second quarter of 2026. The company achieved greater than 100% growth in both revenue and new customers for the quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026, as procedure volume also increased.
This performance follows the Full Market Release of the LIBERTY System on April 13, 2026, with new adoptions by leading health systems in several U.S. states. Microbot also expanded distribution through an agreement with Lovell Government Services to access federal healthcare systems. The company grew its U.S. sales footprint from 4 to 8 territories during the quarter and aims for 12 by year-end, received marketing clearance in Israel as its first market outside the U.S., and agreed to establish a second manufacturing site to support rising demand.
Microbot Medical Inc. has entered into a Letter of Agreement with Sanmina Corporation to manufacture its LIBERTY® Endovascular Robotic System. Sanmina will serve as an additional manufacturing site, giving Microbot more capacity to meet expected demand from existing and new customer accounts.
The company states that expanding manufacturing with a global contract manufacturer is part of its cost reduction strategy. It expects the arrangement to improve operating efficiencies, lower costs, and support higher gross margins as LIBERTY adoption grows in the U.S. and internationally, including Israel and markets where it is pursuing CE Mark and other registrations.
Microbot Medical Inc. filed a current report noting that it has won the Innovative Start-Up Award from Surgical Robotics Technology for its LIBERTY® Endovascular Robotic System. LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
The company reports continued adoption and increased use of LIBERTY following its Full Market Release in early April, including use at leading academic centers across several U.S. states. Management and SRT highlight the system’s innovative design, potential broad healthcare impact, and its aim to improve precision, efficiency, and safety in endovascular care.
Microbot Medical Inc. filed a current report describing new commercial progress for its LIBERTY® Endovascular Robotic System. A globally recognized academic center headquartered in Pennsylvania became the first health system in that state to adopt LIBERTY, joining existing customers in New York City and Boston.
The new customer operates multiple hospitals and multispecialty centers across Pennsylvania and New Jersey, and is the company’s second customer with facilities spanning two states. Microbot now has accounts in seven Eastern U.S. states and, following its recent full market release, plans to expand its sales footprint to the West Coast and further into international markets. A recent agreement expanding access to LIBERTY across certain U.S. federal healthcare systems, including veterans and military patient populations, is also highlighted.
Microbot Medical Inc. has entered into a vendor agreement with Lovell Government Services, creating an opportunity to sell its LIBERTY® Endovascular Robotic System at more than 2,000 U.S. government healthcare facilities, including those of the VA, Department of Defense and Indian Health Service.
Lovell, a Service-Disabled Veteran-Owned Small Business, will list the LIBERTY System on its Federal Supply Schedule contract, with activation expected during the third quarter of 2026, and make it available through platforms such as GSA Advantage, ECAT and DAPA. The relationship is intended to streamline procurement and support broader awareness and adoption across federal healthcare systems.
Microbot Medical Inc. announced that one of the largest healthcare systems in Michigan has become its first Midwest-based account to adopt the LIBERTY Endovascular Robotic System. This follows its first healthcare system customer in North Carolina, showing broader regional uptake across key U.S. markets.
LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, targeting a U.S. market of approximately 2.5 million procedures annually. The system also recently received regulatory approval in Israel, allowing marketing and sales there as the company advances its full market release strategy.